Lightnews — Scholar-powered news

Antonio Ciaccia @aciaccia.bsky.social · 1d

From Big 3 to just zero: Rite Aid is officially reduced to ashes as pharmacy market attrition rolls on @martyschladen.bsky.social ohiocapitaljournal.com/2025/10/13/a...

After bailing on Ohio and Michigan, Rite Aid closes completely • Ohio Capital Journal

A wave of pharmacy closures in Ohio and elsewhere appears to be deepening. Once the third-largest pharmacy chain in the United States, Rite Aid announced on its website that all of its stores are now ...

ohiocapitaljournal.com

Antonio Ciaccia @aciaccia.bsky.social · 1d

“Soaking high drug prices as a mechanism to lower premiums is neither a wise nor a sustainable practice.”

Acknowledge @repauchincloss.bsky.social 🎙️

www.realpharma.co/where-policy...

Where Policy Meets the Pharmacy Counter

Where Policy Meets the Pharmacy Counter Featuring Congressman Jake Auchincloss Episode Summary In this episode of RealPharma , hosts Na-Ri Oh and Ian Wendt sit down…

www.realpharma.co

Antonio Ciaccia @aciaccia.bsky.social · 5d

When Amazon makes moves in pharmacy – no matter how seemingly small – you should always be thinking about the long game @nyeungs.bsky.social

endpoints.news/whats-behind...

What's behind Amazon’s in-person pharmacy play

Amazon to install prescription medication dispensing machines at One Medical clinics, starting in Los Angeles this December, marking its first in-person pharmacy presence.

endpoints.news

Antonio Ciaccia @aciaccia.bsky.social · 5d

Good news for fans of generic drug affordability 👇

www.wsj.com/health/pharm...

Exclusive | Trump Excludes Generics From Big Pharma Tariff Plan

The administration has been weighing duties for months on a range of products and ingredients in a national-security tariff investigation.

www.wsj.com

Antonio Ciaccia @aciaccia.bsky.social · 5d

“American businesses should not be left to subsidize the lack of transparency, accountability and fair competition in the health care industry.”

www.washingtontimes.com/news/2025/oc...

Congress must address the health care cost crisis now

Our health care system has a pressing need for greater competition and transparency.

www.washingtontimes.com

Antonio Ciaccia @aciaccia.bsky.social · 12d

The price is the price.

Unless it’s the other price.

Generic drug prices are going up and down – depending on your perspective.

www.46brooklyn.com/research/are...

Are generic drug prices going up or down? Depends on which benchmark you ask — 46brooklyn Research

For the first time: Year-over-year generic drug price inflation For those unfamiliar, our team at 46brooklyn Research have a thing for tracking prescription drug prices. Not just the prices of d...

www.46brooklyn.com

1

Antonio Ciaccia @aciaccia.bsky.social · 12d

“The immediate stock reaction across the group affirms our view this is more optics than bite.”

Good rundown on yesterday’s Trump/Pfizer rendezvous from @elaineywchen.bsky.social

www.statnews.com/2025/09/30/w...

Will the White House drug-pricing deal lower costs for Americans? Experts are skeptical

Will the White House drug-pricing deal lower costs for Americans? Experts are skeptical.

www.statnews.com

1 1

Antonio Ciaccia @aciaccia.bsky.social · 18d

If you are someone who wants more drug manufacturing in the U.S., this may please you.

If you are someone who wants lower brand drug prices in the U.S., this may tariffy you.

www.usatoday.com/story/money/...

Trump announced new drug tariffs. How much will you pay at the pharmacy counter?

President Donald Trump announced 100% tariffs on brand drugs. Companies that build a U.S. manufacturing plant will be exempt.

www.usatoday.com

1

Antonio Ciaccia @aciaccia.bsky.social · 18d

Look out below!

www.reuters.com/business/hea...

Sanofi set to offer insulin products at $35 per month for all US patients

French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status.

www.reuters.com

1 1

Antonio Ciaccia @aciaccia.bsky.social · 19d

Yeah, that’ll fix it.

www.bloomberg.com/news/article...

1

Antonio Ciaccia @aciaccia.bsky.social · 22d

There are 281 brand-name drugs with new list prices.

Here are the details.

A quarterly-ish review of U.S. drug price changes — 46brooklyn Research

As a non-profit, we at 46brooklyn have made it our goal to provide insights into U.S. drug pricing data available in the public domain based upon the figures we are able to get our nerdy hands on. Whi...

www.46brooklyn.com

1

Antonio Ciaccia @aciaccia.bsky.social · Sep 13

Another state attorney general digs into drug pricing bloat and dysfunction 👇

www.oag.state.va.us/media-center...

1 1 1

Antonio Ciaccia @aciaccia.bsky.social · Sep 9

As a long-time fan of his show, it was awesome to join Clay Farris for a discussion about American drug pricing dysfunction.

mostlymedicaid.com/medicaid-con...

1 1

Antonio Ciaccia @aciaccia.bsky.social · Sep 1

When it rains, it pours.

UnitedHealth Ongoing Criminal Probe Is Broader Than Medicare

The US Justice Department’s criminal division is digging into UnitedHealth Group Inc.’s prescription management services as well as how it reimburses its own doctors under an ongoing probe into the fi...

www.bloomberg.com

1 1

Antonio Ciaccia @aciaccia.bsky.social · Aug 23

“The current system is riddled with barriers to innovation, shielded by exclusivity protections and mired in anticompetitive practices — which help ensure high drug prices persist.”

@blueshieldca.bsky.social www.healthcaredive.com/news/drug-in...

Drug innovation should benefit patients. PBMs are preventing that from happening.

Health plans should directly contract with drug manufacturers to provide medications at transparent and affordable prices, argues Kathy Chang, head of trade relations at Blue Shield of California.

www.healthcaredive.com

2

Reposted by Antonio Ciaccia

sstrumello @sstrumello.bsky.social · Aug 17

Potential positives and negatives aside, pharm-to-table is a band-aid on a mortal wound. @aciaccia.bsky.social www.ajmc.com/view/direct-...

Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

www.ajmc.com

1 1

Antonio Ciaccia @aciaccia.bsky.social · Aug 20

Behold the power of whistleblowers: $289.9 million set to come back to US government and certified G, Sarah Behnke

CVS unit must pay $290 million in drug whistleblower lawsuit, judge rules

A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it overcharged Medicare for prescription drugs.

www.reuters.com

Antonio Ciaccia @aciaccia.bsky.social · Aug 18

The policy ground is shifting on the 340B program, which means the system's current winners and losers have their eyes on how proposed changes could impact their financial realities

340B rebate pilot tees up healthcare industry firestorm

Drugmakers want to convert 340B discounts to rebates under a federal pilot program set to launch in January. Providers are anxious.

www.modernhealthcare.com

Antonio Ciaccia @aciaccia.bsky.social · Aug 14

So essentially, the early yield of the push to bring US drug prices in line with other nations is just exporting American drug pricing distortions.

Eli Lilly says it will raise drug prices in Europe to ‘make them lower’ in U.S.

Eli Lilly said it would raise drug prices in Europe to "make them lower" in U.S., though the actual impact on most patients abroad remains unclear.

www.statnews.com

1 1

Antonio Ciaccia @aciaccia.bsky.social · Aug 7

“We’re trying to disrupt an industry that needs disrupted.”

Testify, Mark.

@gianteagle.bsky.social @mcuban.bsky.social @costplusdrugs.com

triblive.com/news/health-...

'We're trying to disrupt an industry': Mark Cuban touts pharmacy deal with Giant Eagle

Mark Cuban, the billionaire and Western Pennsylvania native now knee-deep in the pharmaceutical industry, offered strong words Wednesday toward the pharmacy benefit managers some say are bleeding drug...

triblive.com

1

Antonio Ciaccia @aciaccia.bsky.social · Jul 30

Had a great discussion with @matthewstoller.bsky.social and @ddayen.bsky.social about PBMs, pharmacies, manufacturers, Medicaid, and how misguided public policies have yielded bloated drug prices and an over-reliance on conflicted intermediaries

www.organizedmoney.fm/p/the-pbm-hi...

The PBM Hitman

Welcome to the podcast Organized Money.

www.organizedmoney.fm

1

Antonio Ciaccia @aciaccia.bsky.social · Jul 22

Decades after retreating from their former marriages, PBMs are blending their DNA with drug companies once again, this time through private labelling.

Here's what it means for the costs of medicines.

Our latest:

How PBMs can use private-labelled drug products as a great escape from anti-steering policies — 46brooklyn Research

Across every corner of U.S. healthcare, from end-of-life care to reproductive rights, patient choice sits squarely in the middle of many health policy questions. From a certain point of view, patient ...

www.46brooklyn.com

1

Antonio Ciaccia @aciaccia.bsky.social · Jul 21

It's a tough time for pharmacies, but for some, it's not all doom and gloom.

If you are a PBM-affiliated pharmacy or are benefitting from 340B spreads, you are well positioned to weather the current financial storm.

And if you are benefitting from both, enjoy the long ride.

What Options Do Retail Pharmacies Have to Become Profitable?

As challenges mount, retail pharmacies that are not affiliated with a PBM or have access to 340B pricing have few options to become profitable.

aishealth.mmitnetwork.com

Antonio Ciaccia @aciaccia.bsky.social · Jul 19

Thanks!

Antonio Ciaccia @aciaccia.bsky.social · Jul 19

Strongest signs yet that Delta Airlines could be getting into the drug business

fortune.com/2025/07/16/d...

Delta moves toward eliminating set prices in favor of AI that determines how much you personally will pay for a ticket

The airline touted a partnership with an AI-enabled revenue system as a step on the road to fully personalized ticket pricing, part of its goal to raise profit margins long-term.

fortune.com

1